Qualigen Therapeutics' Novel Direct Pan-RAS Inhibitors Presented at American Association of Cancer Research (AACR) 2024 Annual Meeting

Poster Includes Preclinical Data on Novel Direct Pan-RAS Inhibitors CARLSBAD, Calif., April 10, 2024 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (“Qualigen” or “the Company,” Nasdaq: QLGN) today announces a poster presentation on its preclinical Novel Direct Pan-RAS Inhibitors was presented at the American Association for Cancer Research (AACR) Annual Meeting 2024 held April 5 – 10 in San Diego, California. “We continue to see cancers developing resistance to current clinical agents that tar

Related Keywords

Kentucky ,United States ,University Of Louisville ,San Diego ,California ,American ,Geoff Clark ,John Trent ,Michael Poirier ,Mike Sabo ,Joe Burlison ,Rob Monsen ,Howard Donninger ,Rachel Ferril ,Tariq Arshad ,Geoffreyj Clark ,Nasdaq ,American Association For Cancer Research ,Qualigen Therapeutics Inc ,Poster Includes ,Preclinical Data ,Novel Direct ,American Association ,Cancer Research ,Annual Meeting ,Chief Executive ,Malignant Peripheral Nerve Sheath Tumors ,Qualigen Therapeutics ,